ArticleNeuro-oncology2014
Prognostic factors associated with survival in patients with symptomatic spinal bone metastases: a retrospective cohort study of 1,043 patients.
Article in Neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 5 syntheses or guidelines pooled it, 166 citations in OpenAlex.
- Prognostic scores for survival as decisional support for surgery in spinal metastases: a performance assessment systematic review.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2021Pooled it
- Visceral Metastasis: A Prognostic Factor of Survival in Patients with Spinal Metastases.Orthopaedic surgery · 2020Pooled it
- Systematic Review of the Role of Stereotactic Radiotherapy for Bone Metastases.Journal of the National Cancer Institute · 2019Pooled it
- Prognostic effect of factors involved in revised Tokuhashi score system for patients with spinal metastases: a systematic review and Meta-analysis.BMC cancer · 2018Pooled it
- A systematic review of prognostic factors predicting survival in patients with spinal bone metastases.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2018Pooled it
- Resistance training concomitant to radiotherapy of spinal bone metastases - survival and prognostic factors of a randomized trial.Radiation oncology (London, England) · 2016Trial
- The transformative role of SBRT in the management of spinal metastases.Nature reviews. Clinical oncology · 2026Review
- A novel inflammatory-nutritional nomogram for predicting survival after minimally invasive surgery for spinal metastases: a comparison with the Katagiri and SORG systems.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Residence in a rural setting is associated with lower five-year survival rates in patients that undergo spine surgery for breast cancer metastatic to the spine: A propensity matched analysis.North American Spine Society journal · 2026Article
- Exploring clinical and demographic determinants of time to treatment in spinal metastases: A Large-Scale cohort study of more than 1000 patients.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Cancer-specific survival patterns in patients with bone metastasis: a registry-based analysis of 13,742 patients.Scientific reports · 2026Article
- Improved outcomes of cyberknife stereotactic radiosurgery for spinal metastases: a retrospective study of sixty-one cases in one single center.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Validation of nine prognostic models in patients with bone metastases undergoing surgery.Journal of orthopaedic surgery and research · 2025Article
- Comparative Outcomes in Metastatic Spinal Cord Compression and Femoral Metastatic Disease: Distinct Clinical Entities with Divergent Prognoses?Medicina (Kaunas, Lithuania) · 2025Article
- The use of the Baumber scoring system for metastatic disease of the vertebral column.BMC research notes · 2025Article
- Combined interdisciplinary treatment of metastatic bone lesions using 3D robot-assisted image-guided navigation : Embolization, biopsy, ablation, and surgery in one operative session.Operative Orthopadie und Traumatologie · 2025Article
- Determinants of Overall and Readmission-Free Survival in Patients with Metastatic Epidural Spinal Cord Compression.Cancers · 2024Article
- Prognostic assessment of patients with bone metastatic renal cell cancer treated with palliative radiotherapy.Oncology letters · 2024Article
- Management of metastatic bone disease of the pelvis: current concepts.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2024Review
- Preoperative Albumin and Postoperative CRP/Albumin Ratio (CARS) are Independent Predictive Factors in Estimating 1-Year Mortality in Patients Operated for Proximal Femoral Metastasis with Endoprosthesis.Indian journal of orthopaedics · 2024Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExpected survival is a major factor influencing extent of treatment for symptomatic spinal bone metastases (SBM). Predictive models have been developed, but their use can lead to over- or undertreatment.. The study objective was to identify prognostic factors associated with survival in patients with symptomatic SBM and to create a validated risk stratification model.
methodsAll patients who were treated for symptomatic SBM between 2001 and 2010 were included in this single center retrospective study. Medical records were reviewed for type of primary cancer, performance status, presence of visceral, brain and bone metastases, number and location of spinal metastases, and neurological functioning. Performance status was assessed with the Karnofsky performance score and neurological functioning with the Frankel scale. Analysis was performed using Kaplan-Meier curves, univariate log-rank tests, Cox regression models, and Harrell's C statistic.
resultsA total of 1 043 patients were studied. The most prevalent tumors were those of breast (n = 299), lung (n = 250), and prostate (n = 215). Median follow-up duration was 6.6 years, and 6 patients were lost to follow-up. Based on the results of the uni- and multivariate analyses, 4 categories were created. Median survival in category A was 31.2 months (95% CI, 25.2-37.3 months), 15.4 months (95% CI, 11.9-18.2 months) for category B, 4.8 months (95% CI, 4.1-5.4 months) for category C, and 1.6 months (95% CI, 1.4-1.9 months) for category D. Harrell's C statistic was calculated after the model was applied to an external dataset, yielding a result of 0.69.
conclusionAssessing patients according to the presented model results in 4 categories with significantly different survival times.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.